- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00801918
Denileukine Diftitox for Relapsed ALCL
A Phase II Pilot Multicenter Study of Denileukin Diftitox Alone and in Combination With ICE (ICED) Chemotherapy in Children, Adolescents and Young Adults (CAYA) With Relapsed or Refractory Anaplastic Large Cell Lymphoma
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
New York
-
New York, New York, United States, 10032
- Columbia University Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age: Patients must be ≥ 2.00 year and ≤ 24.99 years of age at the time of study entry.
- Diagnosis:
Patients must have previous histologic verification of anaplastic large cell lymphoma (ALCL). Patients must be in first, second or third relapse or initial induction failure.
- Disease Status: Patients must have measurable radiographic disease.
- Performance Level: Karnofsky > 60% for patients > 16 years of age and Lansky > 60 for patients <16 years of age. Patients who are unable to walk because of paralysis, but who are up in a wheelchair, will be considered ambulatory for the purpose of assessing the performance score.
- Prior Therapy
Patients must have fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to entering this study. Patients who are post-allogeneic transplant should be off immunosuppressive agents prior to starting therapy. Steroid doses should also be stable or decreasing for at least 1 week prior to starting therapy.
Myelosuppressive chemotherapy: Must not have received within 2 weeks of entry onto this study (6 weeks if prior nitrosourea).
Biologic (anti-neoplastic agent): At least 7 days since the completion of therapy with a biologic agent. For agents that have known adverse events occurring beyond 7 days after administration, this period must be extended beyond the time during which adverse events are known to occur. These patients must be discussed with the Study Chair on a case-by-case basis.
XRT: > 2 wks for local palliative XRT (small port); > 2 months must have elapsed if prior TBI, craniospinal XRT or if > 50% radiation of pelvis; > 6 wks must have elapsed if other substantial BM radiation.
Stem Cell Transplant or Rescue: No evidence of active graft vs. host disease and > 2 months must have elapsed since SCT.
Patients may not have received prior therapy with Denileukin Diftitox
- Organ Function Requirements
Adequate Bone Marrow Function Defined As:
For patients without bone marrow involvement:
- Peripheral absolute neutrophil count (ANC) > 1,000
- Platelet count > 100,000 (transfusion independent)
- Hemoglobin > 8.0 gm (RBC transfusion independent)
For patients with bone marrow involvement:
- Peripheral absolute neutrophil count (ANC) > 1,0
- Platelet count > 20,000 (may receive platelet transfusions)
- Hemoglobin > 8.0 (may receive RBC transfusions)
Adequate Renal Function Defined As:
Creatinine clearance or radioisotope GFR 70mL/min/1.73m2
OR
A serum/plasma creatinine GFR calculation using the Schwartz formula (Schwartz et al. J. Peds, 106:522, 1985)
Estimated Creatinine Clearance (in mL/min/1.73 m2) = (k)(L)/Pcr
Where L = child's length in cm Pcr = plasma (or serum) creatinine (in mg/dL)
k Values = 0.33 low birth weight infant 0.45 term infant 0.55 child 0.55 adolescent female 0.70 adolescent male
Adequate Liver Function Defined As:
- Bilirubin (sum of conjugated + unconjugated) < 1.5 x upper limit of normal (ULN) for age, and
- SGPT (ALT) < 3 x upper limit of normal (ULN) for age
- Serum albumin > 2 g/dL.
Exclusion Criteria:
- Patients must not be currently receiving another investigational drug.
- Patients must not be currently receiving other anti-cancer agents.
- Patients must have a negative pregnancy test and Nursing mothers must agree not to breast-feed.
- Patients who have a documented uncontrolled infection requiring IV antibiotics
- Patients with CNS disease are not eligible.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: DD Alone
Patients will get Denileukin Diftitox for 5 days every 3 weeks for a total of 4 cycles.
|
Denileukin Diftitox: 18 mcg/kg/day: days 1-5 in cycles 1,2,3,4
Other Names:
|
Experimental: DD with ICE Chemotherapy
For patients who show a response to DD alone after 4 cycles or for patients who show progressive disease after 2 cycles, DD will be given with ICE chemotherapy for 2 cycles.
|
Denileukin Diftitox: 18 mcg/kg/day days 1-2 in cycles 5 and 6 Ifosfamide: 3000mg/m²/IV/d X 3 days + Mesna 3000 mg/m2/d X 3 days Carboplatin: 635mg/m2/d X 1 day Etoposide: 100mg/m2/d X 3 days
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Toxicity
Time Frame: 5 months
|
5 months
|
Determine response rate
Time Frame: 6 months
|
6 months
|
Evaluate safety of combination of Denileukin Diftitox and ICE chemotherapy
Time Frame: 6 months
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Biology Studies of ALCL
Time Frame: 6 months
|
6 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Mitchell S Cairo, MD, Columbia University
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Lymphatic Diseases
- Immunoproliferative Disorders
- Lymphoma, Non-Hodgkin
- Lymphoma, T-Cell
- Lymphoma
- Lymphoma, Large-Cell, Anaplastic
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Peripheral Nervous System Agents
- Enzyme Inhibitors
- Analgesics
- Sensory System Agents
- Analgesics, Non-Narcotic
- Antirheumatic Agents
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Antineoplastic Agents, Alkylating
- Alkylating Agents
- Myeloablative Agonists
- Antineoplastic Agents, Phytogenic
- Topoisomerase II Inhibitors
- Topoisomerase Inhibitors
- Cyclophosphamide
- Etoposide
- Ifosfamide
- Interleukin-2
- Denileukin diftitox
Other Study ID Numbers
- AAAC8963
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Anaplastic Large-Cell Lymphoma
-
Jun ZhuPeking University First Hospital; Peking University People's Hospital; Peking... and other collaboratorsWithdrawnSystemic Anaplastic Large-Cell LymphomaChina
-
National Cancer Institute (NCI)Active, not recruitingAnaplastic Large Cell Lymphoma, ALK-Positive | Ann Arbor Stage II Noncutaneous Childhood Anaplastic Large Cell Lymphoma | Ann Arbor Stage III Noncutaneous Childhood Anaplastic Large Cell Lymphoma | Ann Arbor Stage IV Noncutaneous Childhood Anaplastic Large Cell LymphomaUnited States
-
Seagen Inc.CompletedLarge Cell LymphomaUnited States
-
Bristol-Myers SquibbWithdrawnLymphoma, Large-CellUnited States, France
-
University of WashingtonNational Cancer Institute (NCI)WithdrawnAnaplastic Large Cell Lymphoma, ALK-Positive | CD30-Positive Neoplastic Cells Present | Systemic Anaplastic Large Cell LymphomaUnited States
-
Children's Cancer Group, ChinaQilu Hospital of Shandong University; Shanghai Children's Medical Center; West... and other collaboratorsRecruitingPediatric Anaplastic Large Cell LymphomaChina
-
Baylor College of MedicineThe Methodist Hospital Research Institute; Center for Cell and Gene Therapy...Not yet recruitingHodgkin Lymphoma | Non-Hodgkin Lymphoma | Peripheral T-cell Lymphoma | Anaplastic Large Cell Lymphoma, ALK-Positive | Anaplastic Large Cell Lymphoma, ALK-negative | CD30-Positive Diffuse Large B-Cell Lymphoma | Anaplastic Large Cell Lymphoma, T Cell and Null Cell TypeUnited States
-
University Hospital, ToulouseInstitut National de la Santé Et de la Recherche Médicale, FranceActive, not recruitingALK-Positive Anaplastic Large Cell LymphomaFrance
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.UnknownRelapsed/Refractory Anaplastic Large Cell Lymphoma (ALCL)China
-
Fox Chase Cancer CenterWithdrawnAnaplastic Large Cell Lymphoma, ALK-PositiveUnited States
Clinical Trials on Denileukin Diftitox
-
Eastern Cooperative Oncology GroupNational Cancer Institute (NCI)Completed
-
National Cancer Institute (NCI)TerminatedLeukemia, Adult T-CellUnited States
-
Eisai Co., Ltd.CompletedPeripheral T-Cell LymphomaJapan
-
Jonsson Comprehensive Cancer CenterNational Cancer Institute (NCI)CompletedLymphomaUnited States
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)Completed
-
The University of Texas Health Science Center at...CompletedEpithelial Ovarian Cancer | Fallopian Tube Carcinoma | Extraovarian Peritoneal CancerUnited States
-
Pharmatech OncologyUnknownLymphoma | LeukemiaUnited States
-
National Cancer Institute (NCI)CompletedKidney Cancer | Melanoma (Skin)United States
-
Eisai Inc.CompletedLymphoma, B-CellUnited States
-
Eisai Inc.No longer available